Peripheral Blood Stem Cell

Phase 2Cell therapy

FFred Hutchinson Cancer Center

Peripheral Blood Stem Cell is one of 41 biologic programs targeting Fanconi Anemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fanconi AnemiaRecruiting

Stem Cell TransplantationRecruiting

Acute Leukemia of Ambiguous LineageRecruiting

Fanconi AnemiaPhase 2

Recruiting

Stem Cell TransplantationPhase 2

Recruiting

Acute Leukemia of Ambiguous LineagePhase 2

Recruiting

Competition

Competitive Landscape

21 competitors in Acute Leukemia of Ambiguous Lineage

#DrugCompanyPhaseTrials

Mozobil

GGenzyme, a Sanofi Company

Cytosar

6 3

Trexall

Jazz Pharmaceuticals

Phase 2

5 4

Oncovin

Eli Lilly

Phase 2

3 5

Idamycin

Pfizer

Phase 2

2 6

Fludara

Sanofi

Phase 2

2 7

Fludara

Sanofi

Phase 2

2 8

Oncovin

Eli Lilly

Phase 2

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 2

4 10

Decadron

AAspen Global Incorporated

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Stem Cell Transplantation

NCT04224558

Q4 2028

Phase 2Recruiting

Fanconi Anemia

NCT02143830

Q2 2029

Phase 2Recruiting

Acute Leukemia of Ambiguous Lineage

NCT07046078

Q4 2030

Phase 2Recruiting

Acute Leukemia

NCT03970096

Clinical

Trials by Indication[1]

Stem Cell Transplantation1 trial

Stem Cell Transplantation in Crohn's Disease

Recruiting·—·Phase 1/2·NCT04224558·15 enrolled

Fanconi Anemia1 trial

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Recruiting·—·Phase 2·NCT02143830·70 enrolled

Acute Leukemia1 trial

A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Transplantation Cyclophosphamide (PTCy)

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03970096·120 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

Pilot Study of FLAG-Ida Followed Immediately by Reduced-Intensity Allogeneic HCT for Adults Age 60 and Older With Newly Diagnosed Adverse-Risk AML or Other High-Grade Myeloid Neoplasm

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07046078·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Peripheral Blood Stem Cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peripheral Blood Stem Cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peripheral Blood Stem Cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fred Hutchinson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: FFred Hutchinson Cancer Center

Peripheral Blood Stem Cell

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Q2 2029

Q4 2030

Trials by Indication[1]

Stem Cell Transplantation1 trial

Fanconi Anemia1 trial

Acute Leukemia1 trial

Acute Leukemia of Ambiguous Lineage1 trial

References

Drug Info

Quick Facts

Related News